Zimelidine

Zimelidine

Clinical data
Pregnancy category	?
Routes of administration	Oral
ATC code	N06AB02 (WHO)
Legal status
Legal status	Withdrawn from market
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Elimination half-life	8.4 +/- 2.0 hours (parent compound) 19.4 +/- 3.6 hours (norzimelidine)
Excretion	?
Identifiers
IUPAC name 3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-3-yl-prop-2-en-1-amine
CAS Number	56775-88-3 60525-15-7 (anhydrous dihydrochloride), 61129-30-4 (dihydrochloride monohydrate)
PubChem CID	41987
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C16H17BrN2
Molar mass	317.224

WikiDoc Resources for Zimelidine
Articles
Most recent articles on Zimelidine Most cited articles on Zimelidine Review articles on Zimelidine Articles on Zimelidine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Zimelidine Images of Zimelidine Photos of Zimelidine Podcasts & MP3s on Zimelidine Videos on Zimelidine
Evidence Based Medicine
Cochrane Collaboration on Zimelidine Bandolier on Zimelidine TRIP on Zimelidine
Clinical Trials
Ongoing Trials on Zimelidine at Clinical Trials.gov Trial results on Zimelidine Clinical Trials on Zimelidine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Zimelidine NICE Guidance on Zimelidine NHS PRODIGY Guidance FDA on Zimelidine CDC on Zimelidine
Books
Books on Zimelidine
News
Zimelidine in the news Be alerted to news on Zimelidine News trends on Zimelidine
Commentary
Blogs on Zimelidine
Definitions
Definitions of Zimelidine
Patient Resources / Community
Patient resources on Zimelidine Discussion groups on Zimelidine Patient Handouts on Zimelidine Directions to Hospitals Treating Zimelidine Risk calculators and risk factors for Zimelidine
Healthcare Provider Resources
Symptoms of Zimelidine Causes & Risk Factors for Zimelidine Diagnostic studies for Zimelidine Treatment of Zimelidine
Continuing Medical Education (CME)
CME Programs on Zimelidine
International
Zimelidine en Espanol Zimelidine en Francais
Business
Zimelidine in the Marketplace Patents on Zimelidine
Experimental / Informatics
List of terms related to Zimelidine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Zimelidine (Normud®, Zelmid®) was the first marketed selective serotonin reuptake inhibitor (SSRI) antidepressant. It is a pyridylallylamine, structurally different from other antidepressants. The substance was developed in the early 1980s by the Swedish company Astra AB following a search for drugs with structures similar to chlorpheniramine (it is a derivative of Chlorphenamine), an antihistamine with antidepressant activity. It was then licensed to other drug producers.

Zimelidine has been banned worldwide due to serious, sometimes fatal, cases of central and/or peripheral neuropathy known as Guillain-Barré syndrome and due to a peculiar hypersensitivity reaction involving many organs including skin exanthema, flu-like symptoms, arthralgias, and sometimes eosinophilia. Additionally, zimelidine was charged to cause an increase in suicidal ideation and/or attempts among depressive patients. After its ban, it was succeeded by fluvoxamine and fluoxetine (derived from the antihistamine diphenhydramine) in that order, and the other SSRIs.

Mechanism of action

The mode of action is a strong reuptake inhibition of serotonin from the synaptic cleft. Postsynaptic receptors are not acted upon.

Other uses

Zimelidine was reported by Montplaisir and Godbout to be very effective for cataplexy in 1986, back when this was usually controlled by tricyclic antidepressants, which often had anticholinergic effects. Zimelidine was able to improve cataplexy without causing daytime sleepiness.

Side effects

Most often reported were:

• Dry mouth, dryness of pharyngeal and nasal membranes
• Increased sweating (hyperhidrosis)
• Vertigo
• Nausea

Interactions

• MAO inhibitors - severe or life-threatening reactions possible

Dosage

The former doses were 200 to 400mg daily in outpatients and up to 600mg in inpatients.

References

• PubChem Substance Summary: Zimelidine National Center for Biotechnology Information.
• Bruce G. Charlton, Self-management of psychiatric symptoms using over-the-counter (OTC) psychopharmacology: the S-DTM therapeutic model - self-diagnosis, self-treatment, self-monitoring. Medical Hypotheses 2005; 65: 823-828.

1. ^ Caille G, Kouassi E, de Montigny C. (1986). "Pharmacokinetic study of zimelidine using a new GLC method". Clinical Pharmacokinetics. 8 (6): 530–40. PMID 6228368.CS1 maint: Multiple names: authors list (link)
2. ^ Godbout R, Montplaisir J. (1986). "The effect of zimelidine, a serotonin-reuptake blocker, on cataplexy and daytime sleepiness of narcoleptic patients". Clinical Neuropharmacology. 9 (1): 46–51. PMID 2950994.
3. ^ see Godbout et al. 1986